Targeting study of gelatin adsorbed clodronate in reticuloendothelial system and its potential application in immune thrombocytopenic purpura of rat model

Journal of Controlled Release

Volumn 114, Issue 2, 2006, Pages 202-208

  Li, Peiyong ^a   Tan, Zhonghua ^a   Zhu, Yihua ^b   Chen, Suyun ^b   Ding, Shuli ^b   Zhuang, Hongming ^c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b East China University of Science and Technology   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clodronate; Gelatin nanospheres; Immune thrombocytopenic purpura (ITP); Macrophages

Indexed keywords

CELLS; DRUG PRODUCTS; IMMUNOLOGY; PATIENT TREATMENT; PHYSIOLOGICAL MODELS; PROTEINS;

CLODRONATE; GELATIN NANOSPHERES; IMMUNE THROMBOCYTOPENIC PURPURA (ITP); MACROPHAGES;

BIOMEDICAL ENGINEERING;

CLODRONIC ACID; DRUG CARRIER; GELATIN; NANOPARTICLE; TECHNETIUM 99M; TRACER;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CHEMOPROPHYLAXIS; COLLOID; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STABILITY; DRUG TARGETING; DRUG TISSUE LEVEL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER; LIVER LEVEL; MACROPHAGE; MALE; NANOTECHNOLOGY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM; SCINTIGRAPHY; SPLEEN; TARGET ORGAN; THROMBOCYTE COUNT;

ANALGESICS, NON-NARCOTIC; ANIMALS; CLODRONIC ACID; COLLOIDS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; GELATIN; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; ISOTOPE LABELING; LIVER; MACROPHAGES; MALE; NANOTUBES; PHYTIC ACID; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RATS; RATS, SPRAGUE-DAWLEY; RETICULOENDOTHELIAL SYSTEM; SPLEEN; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 33747892245     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.05.012     Document Type: Article

References (39)

1. Cines D.B., and Blanchette V.S. Immune thrombocytopenic purpura. N. Engl. J. Med. 346 (2002) 995-1008
2. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 349 (1997) 1531-1536
3. Neiman J.C., Mant M.J., and Shnitka T.K. Phagocytosis of platelets by Kupffer cells in immune thrombocytopenia. Arch. Pathol. Lab. Med. 111 (1987) 563-565
4. Gernsheimer T., Stratton J., Ballem P.J., and Slichter S.J. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N. Engl. J. Med. 320 (1989) 974-980
5. Cines D., and Bussel J.B. How I treat: ITP. Blood 106 (2005) 2244-2251
6. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann. Intern. Med. 126 (1997) 307-314
7. Longmuir K.J., Robertson R.T., Haynes S.M., Baratta J.L., and Waring A.J. Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a plasmodium amino acid sequence. Pharm. Res. 23 (2006) 759-769
8. Popielarski S.R., Hu-Lieskovan S., French S.W., Triche T.J., and Davis M.E. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver: 2. In vitro and in vivo uptake results. Bioconjug. Chem. 16 (2005) 1071-1080
9. Alves-Rosa F., Stanganelli C., Cabrera J., van Rooijen N., Palermo M.S., and Isturiz M.A. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 96 (2000) 2834-2840
10. Alves-Rosa F., Vermeulen M., Cabrera J., Stanganelli C., Capozzo A., and Narbaitz M. Macrophage depletion following liposomal-encapsulated clodronate (LIP-CLOD) injection enhances megakaryocytopoietic and thrombopoietic activities in mice. Br. J. Haematol. 121 (2003) 130-138
11. Coester C.J., Langer K., van Briesen H., and Kreuter J. Gelatin nanoparticles by two step desolvation-a new preparation method, surface modifications and cell uptake. J. Microencapsul 17 (2000) 187-193
12. 99mTc-labelled compounds prepared with sodium dithionite as reducing agent. Nuklearmedizin 20 (1981) 283-289
13. 99mTc-labeling of antibodies by sodium dithionite reduction, and role of ascorbate as a stabilizer in cysteine challenge. Nucl. Med. Biol. 23 (1996) 827-835
14. Jiao H., Shen W., Ohe Y., Miura K., Tamura T., and Saijo N. A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro. Cancer Immunol. Immunother. 35 (1992) 412-416
15. Jiao H., Soejima Y., Ohe Y., and Saijo N. A new MTT assay for examining the cytotoxicity of activated macrophages towards the non-adherent P388 leukaemia cell line. J. Immunol. Methods 153 (1992) 265-266
16. Svensson G., Friman S., Jacobsson L., and Holmberg S.B. Hepatocyte and Kupffer cell function after liver transplantation in the rat-in vivo evaluation with dynamic scintigraphy. Liver 15 (1995) 189-195
17. Shiomi S., Kuroki T., Ueda T., Takeda T., Nishiguchi S., and Nakajima S. Diagnosis by routine scintigraphy of hepatic reticuloendothelial failure before severe liver dysfunction. Am. J. Gastroenterol. 91 (1996) 140-142
18. 99mTc-labelled pyrophosphate and related compounds in young rats. Acta Radiol., Ther. Phys. Biol. 15 (1976) 71-80
19. 99mTc administered as microspheres. Radiology 134 (1980) 489-491
20. 99mTc-Sb2S3 colloid in the rodent species. Int. J. Radiat. Appl. Instrum., B Nucl. Med. Biol. 13 (1986) 67-73
21. Thiele L., Rothen-Rutishauser B., Jilek S., Wunderli-Allenspach H., Merkle H.P., and Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?. J. Control. Release 76 (2001) 59-71
22. Roser M., Fischer D., and Kissel T. Surface-modified biodegradable albumin nano- and microspheres: II. Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 46 (1998) 255-263
23. Plosker G.L., and Goa K.L. Clodronate, a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47 (1994) 945-982
24. Mian M., Beghe F., Caprio A., Aloj R., and Bertelli A. Tolerability and safety of clodronate therapy in bone diseases. Int. J. Clin. Pharmacol. Res. 11 (1991) 107-114
25. Atula S.T., Tahtela R.K., Nevalainen J.I., and Pylkkanen L.H. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia. Acta Oncol. 42 (2003) 735-740
26. D'Amelio P., Muratore M., Tinelli F., Tamone C., Cosentino L., and Quarta E. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women. Int. J. Tissue React. 25 (2003) 73-78
27. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9 (2003) 2643-2658
28. Cittanova M.L., Mavre J., Riou B., and Coriat P. Long-term follow-up of transplanted kidneys according to plasma volume expander of kidney donors. Intensive Care Med. 27 (2001) 1830
29. Persson J., and Grande P.O. Volume expansion of albumin, gelatin, hydroxyethyl starch, saline and erythrocytes after haemorrhage in the rat. Intensive Care Med. 31 (2005) 296-301
30. Kumagai T., Yamanaka T., Wataya Y., Umetsu A., Kawamura N., and Ikeda K. Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J. Allergy Clin. Immunol. 100 (1997) 130-134
31. Ozaki T., Nishimura N., Muto T., Sugata K., Kawabe S., and Goto K. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine 23 (2005) 1205-1208
32. Sandler S.G., and Tutuncuoglu S.O. Immune thrombocytopenic purpura - current management practices. Expert Opin. Pharmacother. 5 (2004) 2515-2527
33. Blom A.B., van Lent P.L., Holthuysen A.E., van der Kraan P.M., Roth J., and van Rooijen N. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthr. Cartil. 12 (2004) 627-635
34. Elder A.C., Gelein R., Oberdorster G., Finkelstein J., Notter R., and Wang Z. Efficient depletion of alveolar macrophages using intratracheally inhaled aerosols of liposome-encapsulated clodronate. Exp. Lung Res. 30 (2004) 105-120
35. Espinosa-Heidmann D.G., Suner I.J., Hernandez E.P., Monroy D., Csaky K.G., and Cousins S.W. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 44 (2003) 3586-3592
36. Fidler I.J. Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis. Res. Immunol. 143 (1992) 199-204
37. Van Rooijen N., and Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174 (1994) 83-93
38. Laverman P., Boerman O.C., Oyen W.J.G., Corstens F.H.M., and Storm G. In vivo applications of PEG liposomes: unexpected observations. Crit. Rev. Ther. Drug Carrier Syst. 18 (2001) 551-566
39. Bekersky I., Boswell G.W., Hiles R., Fielding R.M., Buell D., and Walsh T.J. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm. Res. 17 (2000) 1494-1502